慢性淋巴细胞白血病和非霍奇金淋巴瘤：化疗时代的终结？ - Suppr

CLL and NHL: the end of chemotherapy?

作者信息

Cheson Bruce D

机构信息

GEORGETOWN UNIVERSITY HOSPITAL.

出版信息

Blood. 2014 May 29;123(22):3368-70. doi: 10.1182/blood-2014-04-563890.

DOI:10.1182/blood-2014-04-563890

PMID:24876522

Abstract

摘要

相似文献

CLL and NHL: the end of chemotherapy?

Blood. 2014 May 29;123(22):3368-70. doi: 10.1182/blood-2014-04-563890.

Idelalisib has activity in mantle cell lymphoma.

Cancer Discov. 2014 May;4(5):OF8. doi: 10.1158/2159-8290.CD-RW2014-072. Epub 2014 Mar 27.

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

Blood. 2014 May 29;123(22):3398-405. doi: 10.1182/blood-2013-11-537555. Epub 2014 Mar 10.

Idelalisib--a PI3Kδ inhibitor for B-cell cancers.

N Engl J Med. 2014 Mar 13;370(11):1061-2. doi: 10.1056/NEJMe1400055.

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.

Targeting of B-cell receptor signalling in B-cell malignancies.

J Intern Med. 2017 Nov;282(5):415-428. doi: 10.1111/joim.12600. Epub 2017 Mar 14.

Idelalisib, ibrutinib show benefits in CLL.

Cancer Discov. 2014 Apr;4(4):382. doi: 10.1158/2159-8290.CD-NB2014-025. Epub 2014 Feb 20.

Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.

Cancer Biol Ther. 2015;16(2):204-6. doi: 10.1080/15384047.2014.1002369.

B-cell receptor inhibitors in chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2011 Aug;9(8):605-6.

Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.

Target Oncol. 2015 Mar;10(1):141-51. doi: 10.1007/s11523-015-0359-8. Epub 2015 Feb 1.

引用本文的文献

Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.

Sci Rep. 2018 Jul 12;8(1):10590. doi: 10.1038/s41598-018-28619-z.

The B cell receptor signaling pathway in mantle cell lymphoma.

Oncotarget. 2018 Mar 27;9(38):25332-25341. doi: 10.18632/oncotarget.25011. eCollection 2018 May 18.

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.

Adv Ther. 2017 Oct;34(10):2210-2231. doi: 10.1007/s12325-017-0610-z. Epub 2017 Oct 5.

Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

Ann Transl Med. 2017 Feb;5(3):39. doi: 10.21037/atm.2016.12.25.

Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies.

J Clin Transl Hepatol. 2016 Jun 28;4(2):143-50. doi: 10.14218/JCTH.2016.00005. Epub 2016 Jun 15.

Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.

Cancer Biol Ther. 2015;16(2):204-6. doi: 10.1080/15384047.2014.1002369.

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Leuk Lymphoma. 2015;56(11):3031-7. doi: 10.3109/10428194.2015.1023800. Epub 2015 Mar 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

CLL and NHL: the end of chemotherapy?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献